focus -WSS

focus

author：explore 2025-10-01 17:19:21 - browse：865

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： As AI in medicine takes off, can 'human in the loop' prevent harm?

WSS

Why scientists need input from humanists on sensitive research

Wegovy improves function in certain heart failure patients

How the first Native Hawaiian psychiatrist helped diversify medicine

Readout Newsletter: CAR

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Readout Newsletter: CAR

knowledge

focus

entertainment

Medical leaders decry Supreme Court decision on affirmative action

Pushing for an NIH office for post

Heart attack and stroke risk calculators need revising

Ebola: Gilead Sciences antiviral shows promise as new treatment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Readout Newsletter: CAR

As demand for Covid shots wanes, Moderna seeks its next success

PBMs are inflating the cost of generic drugs. They must be reined in

United colonoscopy coverage change 'may cost lives,' doctors say

FDA advisory panel to debate high blood pressure devices

explore

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Pushing for an NIH office for post

PBMs are inflating the cost of generic drugs. They must be reined in

WuXi out of biotech trade group, U.S. and China relations to blame

Can U.S. cancer drug shortages be fixed?

How the drug

Wikipedia

hotspot

hotspot

Wikipedia